Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in pediatric moderate to severe Crohn's disease
2006-004814-41Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in Crohn's disease (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Clinical remission at Week 26. Started May 2007; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2006-004814-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004814-41.